From April 9 to 10, 2025, BIONNOVA 2025 Biopharma Innovators Forum & Exhibition, a pivotal exchange platform in the biomedical industry, was successfully held at Zhangjiang Science Hall in Shanghai. A total of 22 cutting-edge sub-forums were staged concurrently, covering hot technical segments such as antibody and polypeptide drugs, cell and gene therapy, and radionuclide pharmaceuticals, as well as industrial chain supporting topics including process optimization, pharmaceutical packaging materials and drug delivery systems, clinical research and commercialization.

Ms. JIANG Lan, Patent Attorney at Liu Shen & Associates, was invited to the Forum on Cutting-edge Progress of Novel mRNA Technologies and delivered a keynote speech entitled Patent Portfolio Strategies for Nucleic Acid Drugs and Infringement Litigation Case Studies. Drawing on her extensive professional experience as a former patent examiner, in-house IPR manager and seasoned practitioner at Liu Shen, Ms. Jiang comprehensively analyzed core patent subjects and mainstream portfolio strategies in the nucleic acid drug sector. She illustrated the patent thicket deployment tactics adopted by leading pharmaceutical enterprises with practical examples, and elaborated on the significance of rational patent planning and IP risk prevention and control via multiple litigation and patent invalidation cases. Her insightful sharing was well received by all participants, and numerous industry practitioners engaged in in-depth professional discussions with her after the session.

During the event, the Shanghai-based team of Liu Shen actively communicated with visiting guests and industry counterparts on intellectual property legal services, and presented the firm’s full-spectrum service scope and future development priorities.